Citadel Advisors’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-75,500
| Closed | -$305K | – | 12783 |
|
|
2025
Q1 | $305K | Sell |
75,500
-93,900
| -55% | -$313K | ﹤0.01% | 9545 |
|
|
2024
Q4 | $542K | Buy |
169,400
+164,500
| +3,357% | +$558K | ﹤0.01% | 8372 |
|
|
2024
Q3 | $11K | Buy |
4,900
+4,500
| +1,125% | +$10.4K | ﹤0.01% | 13176 |
|
|
2024
Q2 | $860 | Buy |
+400
| New | +$712 | ﹤0.01% | 13901 |
|
|
2024
Q1 | – | Sell |
-24,100
| Closed | -$55.2K | – | 14633 |
|
|
2023
Q4 | $55.2K | Buy |
24,100
+19,400
| +413% | +$42.2K | ﹤0.01% | 11676 |
|
|
2023
Q3 | $7.99K | Hold |
4,700
| – | – | ﹤0.01% | 13227 |
|
|
2023
Q2 | $11.6K | Buy |
4,700
+900
| +24% | +$2.46K | ﹤0.01% | 13133 |
|
|
2023
Q1 | $8.55K | Buy |
3,800
+2,200
| +138% | +$11K | ﹤0.01% | 13650 |
|
|
2022
Q4 | $8.18K | Buy |
1,600
+490
| +44% | +$3.53K | ﹤0.01% | 13762 |
|
|
2022
Q3 | $12K | Sell |
1,110
-2,580
| -70% | -$30.7K | ﹤0.01% | 12222 |
|
|
2022
Q2 | $38K | Sell |
3,690
-3,970
| -52% | -$52K | ﹤0.01% | 12089 |
|
|
2022
Q1 | $136K | Buy |
7,660
+1,730
| +29% | +$37.2K | ﹤0.01% | 11958 |
|
|
2021
Q4 | $184K | Sell |
5,930
-4,630
| -44% | -$153K | ﹤0.01% | 11969 |
|
|
2021
Q3 | $348K | Sell |
10,560
-1,390
| -12% | -$41.1K | ﹤0.01% | 10731 |
|
|
2021
Q2 | $353K | Buy |
+11,950
| New | +$331K | ﹤0.01% | 10866 |
|
Citadel Advisors's CKPT Position: Q1 2025 in Review
Citadel Advisors sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 263 shares — an estimated $877 sold.
Citadel Advisors first reported a position in CKPT in Q2 2020 and held it in 14 quarters. The position peaked at $674K in Q3 2021. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.
- Citadel Advisors reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 263 Checkpoint Therapeutics shares in Q1 2025, an estimated $877.
- Citadel Advisors first reported a position in Checkpoint Therapeutics in Q2 2020 and held it in 14 quarters.
- Citadel Advisors's Checkpoint Therapeutics position peaked at $674K in Q3 2021.
- 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.